Kunming Longjin Pharmaceutical Co., Ltd. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 43.63 million compared to CNY 77.84 million a year ago. Revenue was CNY 43.63 million compared to CNY 78.11 million a year ago.

Net loss was CNY 15.78 million compared to CNY 2.47 million a year ago. Basic loss per share from continuing operations was CNY 0.0394 compared to CNY 0.0062 a year ago. Diluted loss per share from continuing operations was CNY 0.0394 compared to CNY 0.0062 a year ago.